Biktarvy is a complete HIV treatment that combines three powerful medicines to form the smallest 3-drug, integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) available ...

Biktarvy is a 3-drug combination of bictegravir, an HIV-1 integrase strand transfer inhibitor, and emtricitabine and tenofovir alafenamide, both HIV-1 nucleoside analog reverse transcriptase ...

According to Gilead Sciences, no patients with M184V/I who received Biktarvy had HIV RNA ≥50 copies/mL at week 48. No cases of treatment-emergent resistance were reported in the final analysis.

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

Biktarvy, which is used to treat HIV, can cause side effects. Learn about its more common, mild, and serious side effects and how to manage them.

The Advancing Access program covers up to $7,200 in annual copays and there’s no monthly limit for Biktarvy. In fact, 90% of program participants pay $0 for their monthly Biktarvy prescription.

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Biktarvy contains three medicines: bictegravir, emtricitabine, and tenofovir alafenamide. Two of these medicines, emtricitabine and tenofovir alafenamide, have been used to treat HIV for many years.

Biktarvy is used in adults and certain children to treat HIV-1 (the most common type of HIV.) Children receiving Biktarvy must weigh at least 14 kilograms (kg).

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

Biktarvy is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral (ARV) treatment history or to ...